The Penn CFAR Developmental Core Pilot Award Program is designed to assist both faculty member applicants and future faculty (e.g., Instructors, Research Associates, or clinical fellows with a division chief’s commitment to support beyond fellowship) to launch a successful independently funded HIV/AIDS-related project. In addition to funding, this support is provided through mentoring (or collaborative partnerships for more seasoned investigators). Mentoring is available regardless of whether or not an application is funded.
Successful CFAR Pilot Awards focus on any aspect of HIV/AIDS clinical care, epidemiology, virology, immunology, structural biology, vaccine development, or prevention that are determined to be relevant to the goals of our program. Priority is given to junior faculty who have no other funding source and are seeking support for the development of preliminary data for an NIH R01-type application. The University of Pennsylvania CFAR Developmental Core offers two types of pilot awards:
General Pilot Awards: Faculty members
Eligible applicants must have a faculty appointment of at least an Assistant Professor or equivalent at a Penn CFAR institution. It is also acceptable to have an appointment by the award date.
For junior faculty applicants, a one-page mentorship plan with a senior faculty member is strongly encouraged; for non-HIV/AIDS investigators, a partnership plan with an established HIV/AIDS investigator is strongly encouraged. Contact the Developmental Core for assistance with identifying HIV-focused mentorships and partnerships.
Mentored Research Scholar Awards: Young Investigators (Pre-Faculty)
Young investigators at the Instructor, Research Associate, Wistar Staff Scientist, or Wistar Research Assistant Professor level are eligible for mentored awards. Senior fellows will also be considered if they have institutional commitment for a pre-faculty position at the time the award will start. Applicants should be poised to begin an independent research program. If you have any questions about eligibility, please contact the Developmental Core Director (Liz Lowenthal, MD MSCE).
Mentored Research Scholar Award applications must include a letter of support from their scientific mentor. For fellows, an institutional letter of support is also required. In addition to these letters, a one-page mentorship plan is required. Guidelines for the Mentorship Plan are available through the CFAR website.
If you have any questions about eligibility, please contact Developmental Core Director (Liz Lowenthal, MD MSCE).)
|This announcement has been revised to include a new joint pilot opportunity between the CFAR and the Penn Institute for RNA Innovation.|
The Penn Center for AIDS Research (Penn CFAR) invites Pilot Grant applications. All areas of HIV/AIDS are acceptable including clinical, basic, behavioral and implementation science research. This year, we especially encourage projects focused on:
- HIV & Aging*
- Implementation Science*
- Single cell HIV reservoirs and immune analysis*
- Research on the impact of HIV Communication and Policy (see p.3 for more information)*
- Applying modified RNA technology to HIV research^ with joint funding from the Penn Institute for RNA Innovation.
*Pilot projects for investigators without prior R01-level funding in HIV/AIDS
^Open to all investigators, including those who have been previously funded (in or out of the HIV/AIDS field), as long as the proposal reflects a major new research direction involving applications of modified RNA technology.
Pilot projects are intended to lead to independent HIV/AIDS funding.
All proposals must address high or medium priority areas in the NIH Priorities for HIV/AIDS: https://www.oar.nih.gov/hiv-policy-and-research/research-priorities
Pilot Award eligibility criteria include:
- New investigators without prior R01 level funding from NIH
- Established investigators who have not previously been funded by the NIH for work in HIV/AIDS.
Two types of pilot award are available:
The award types are described below.
(*Note that researchers who are not eligible for these awards may be eligible for CFAR microgrants which are awarded on a rolling basis throughout the year: https://www.med.upenn.edu/cfar/microgrants.html.)
Amount: Awards are for a maximum of $50,000 per grant*. Applications for smaller awards are encouraged. Applicants should provide justification for the proposed budget. Grants are for one-year and are not renewable. IRB approvals must be in place before funds can be dispersed.
Application Details: The required cover page and instructions can be found here: CFAR Pilot Cover Pg and Instructions 2024-1.
Application Deadline: January 30, 2024
Funding release expected: July 1, 2024
AWARD TYPES AND ELIGIBILITY
Eligible applicants must have a faculty appointment of at least Assistant Professor or its equivalent at a Penn CFAR institution. It is also acceptable to have an appointment by the award date.
For junior faculty applicants, a one-page mentorship plan with a senior faculty member is strongly encouraged; for non-HIV/AIDS investigators, a partnership plan with an established HIV/AIDS investigator is strongly encouraged. Contact the Developmental Core leadership for assistance with identifying HIV-focused mentors and partnerships.
Young investigators at the Instructor, Research Associate, Wistar Staff Scientist, or Wistar Research Assistant Professor level are eligible for mentored awards. Senior fellows will also be considered if they have institutional commitment for a pre-faculty position at the time the award will start. Applicants should be poised to begin an independent research program. If you have any questions about eligibility, please contact Developmental Core Director (Liz Lowenthal, MD MSCE; firstname.lastname@example.org).
Mentored Research Scholar Award applications must include a letter of support from their scientific mentor. For fellows, an institutional letter of support is also required. In addition to these letters, a one-page mentorship plan is required.
Community-based Organizations & Department of Health: Investigators at partner institutions may be eligible in collaboration with Penn, CHOP, or Wistar faculty. If you have any questions about eligibility, please contact Developmental Core Director (Liz Lowenthal, MD MSCE; email@example.com)
Clinical Studies: The NIH restricts CFAR Pilot Grants from funding NIH-defined “Clinical Trials.” If you are planning to propose a human intervention study (biomedical, behavioral, etc.), please contact Dr. Lowenthal so we can help ensure that your study, if approved, could be supported by available funds.
Use of Fetal Tissue: Research plans using fetal tissue are not permitted in pilot awards.
International Applications: Applications with international components must be approved by the International Core Director (Robert Gross, MD MSCE firstname.lastname@example.org) prior to preparation of the application.
Successful awardees will be required to submit periodic progress reports and to take part in mentoring activities and feedback seminars. Pilot recipients will be followed for at least 5 years after the funding period ends for NIH reporting.
We strongly encourage all applicants to reach out to the Developmental Core prior to submission for help identifying resources including potential investigative partners.
CFAR Pilot Grant RFA Addendum
Pilot grant applicants are encouraged to seek support from CFAR Cores and Scientific Working Groups (SWGs). Cores and SWGs provide resources that often help to expand the impact of HIV research.
For work in Implementation Science, consultation with the IS Core is strongly recommended. Please use this link to schedule: https://upenn.co1.qualtrics.com/jfe/form/SV_cSIVKprCvxbCnQy
To support work related to HIV Communication and Policy, the Penn CFAR is excited to announce the availability of a new HIV Communication and Policy Scientific Working Group (SWG). This SWG is particularly eager to support work in the following areas:
- Understanding the role of policy communication in improving/exacerbating racial ethnic disparities
- Updating the SAVA (Substance Abuse, Violence, HIV/AIDS) syndemic model to include climate change, policy, environment, and the COVID pandemic.
- Novel methods for improving HIV policy communication
- HIV-related information pathologies (misinformation and disinformation): Prevalence, temporal patterns, intended audiences, and topic mixture (where pathologic HIV messages are mixed with others, including political, policy, and healthcare in general)
- Impact of incorrect perceptions and inadequate communication about HIV policies
- Modeling the impact of HIV policy
- Conspiracy theories about infections that disproportionately burden vulnerable groups (e.g., M-Pox and HIV); models that allow us to anticipate future misconceptions
For support from the HIV Communication and Policy SWG, please contact one of the following SWG leaders:
Dolores Albarracin, PhD (Director): email@example.com
John Holmes, PhD, FACE, FACMI (Co-Director): firstname.lastname@example.org
Bita Fayaz-Farkhad, PhD (Co-Director): email@example.com
Elizabeth Lowenthal, MD MSCE
Director, CFAR Developmental Core
The Developmental Core is intended to help pilot grant applicants achieve the following goals:
- Translate the pilot grant application into a subsequent competitive external funding application (i.e., NIH or other agency)
- Gain familiarity with the Penn CFAR and CFAR Cores and services.
- Network with local like-minded professionals. The Core provides opportunities to interact with colleagues in the Penn CFAR and can provide introductions to colleagues working throughout the University of Pennsylvania, The Wistar Institute, and the Children’s Hospital of Philadelphia.
- Identify potential opportunities for extramural collaboration.
- Develop awareness of policies and procedures relevant to the awardee’s work (e.g., clear understanding of human subjects and/or animal research requirements, international research guidelines, good clinical practice).
- Achieve career advancement and work towards independence as HIV-focused researchers.
- Establish an ethically sound research environment.
- Assist applicants whose pilot submissions were not funded to address reviewers’ concerns to achieve success in the following application cycle.
In accepting the Pilot Grant, awardees agree to:
- Obtain all necessary ethical approvals and undergo successful NIH scientific review prior to release of funding. Awardees will complete the NIH Human Subjects Study Record required for all projects with a human subjects component. To determine if your project has a human subjects component, please see the NIH Questionnaire.
- In presentations, abstracts, and publications, acknowledge CFAR funding with either of the following, as appropriate:
- Direct CFAR Funding Support: This research was supported by a grant from the Penn Center for AIDS Research (CFAR), an NIH-funded program (P30 AI 045008).
- Indirect/Partial Funding Support: This publication/presentation/grant proposal was made possible through core services and support from the Penn Center for AIDS Research (CFAR), an NIH-funded program (P30 AI 045008).
- Participate in general professional development activities and research-in-progress sessions, such as Pilot Feedback Talks coordinated by the CFAR Developmental Core, both for added feedback on active awards and to learn more about what others are doing in the CFAR community and opportunities for collaboration.
- Utilize the resources of the CFAR to maximize their research success by participating actively in the program relationship and engaging both chosen and assigned CFAR faculty in the process of transforming the pilot award grant into a subsequent grant submission. Mentored awardees should engage the mentor(s) at all stages of grant preparation, from the initial conception of an idea to the final grant submission.
- The CFAR faculty’s time and the CFAR Developmental Core are valuable resources. The awardee/applicant is responsible for asking for assistance when needed and being fully prepared for mentoring meetings. Preparatory materials such as an agenda, pending papers, drafts of future grant-specific aims, or other information should be provided at least 2 weeks in advance of meetings.
- Mentored pilot awardees must provide the CFAR mentor(s) with a copy of any grant application in a reasonable time (i.e., at least 4 weeks for NIH K- and R-series awards) for feedback. This timeline requires that mentorship starts well before submission (i.e., at least 3 months prior to the due date) to allow for revision and final critical review.
- To monitor the progress of the Pilot project and submission of a subsequent grant application, the awardee must meet at least twice a year, more if indicated in the mentoring plan or as requested by his/her CFAR faculty mentor. Awardees/applicants agree to send a preparatory e-mail to the mentor outlining the topics to be covered and their goals for each mentoring meeting.
- Take advantage of opportunities for collaborative research within the Penn CFAR and other CFARs nationwide.
- Complete brief quarterly progress reports that review progress, spending, highlights, and next steps, and track abstracts/presentations/publications during the period of the award.
- Complete annual surveys for at least 5 years after completion of the award.
Recipients of Developmental Core Pilot Grants in HIV/AIDS
|Fiscal Year||Investigators||Title of Project|
|2024||Nancy Aitcheson, MD, MSHP||PEP-talk: Designing Implementation Strategies for HIV Prevention at Plume|
|2024||Rebecca Clark, PhD, RN||Understanding how pregnant and postpartum women living with HIV make infant feeding choices and their perceptions of related clinician communication|
|2024||Laurence Eisenlohr, VMD, PhD – Joint Pilot, co-sponsored with the Penn Institute for RNA Innovation||Production of T Cell Receptor-Like Antibodies and Monospecific CD4+ T Cells to Study the CD4+ T Cell-Mediated Processing, Presentation and Spread of HIV|
|2024||Brad Johnson, MD, PhD||Modeling the Interplay of HIV and Age-Related Biology|
|2024||Bonnie Ky, MD, MSCE||Understanding Cardiovascular Risk in HIV and Breast Cancer in Botswana|
|2023||Luis Montaner, DVM, MSc, DPhil||Immunopathogenesis of Monkeypox Infection in Virally-suppressed People Living With HIV|
|2023||Florence Momplaisir, MD||Contextual inquiry for the development of a social network strategy intervention to reduce racial inequities in monkeypox vaccination: an HIV status neutral approach|
|2023||David Allman, PhD||Engaging rare B cell precursors in HIV|
|2023||Amelia Escolano, PhD||Targeting premium antibody lineages to streamline anti HIV-1 bNAb development by vaccination|
|2023||Yeonsoo Baik, MPH, PhD||Diagnostic accuracy of GeneXpert Ultra testing for Mycobacterium Tuberculosis on oral swab samples in South Africa|
|2022||Sally Chan, PhD & Dolores Albarracin, PhD – Joint Pilot, co-sponsored with PMHARC||Developing a Machine Learning Method to Increase HIV/HCV Prevention and Care and Substance Use Treatment in People Who Inject Drugs|
|2022||Benjamin Reiner, PhD & Matthew Hayes, PhD – Joint Pilot, co-sponsored with PMHARC||Characterization of rhesus macaque frontal cortex and basal ganglia cell type-specific transcriptomes in a post-SIV infection time course|
|2022||Matthew Schindler, PhD & Dennis Kolson, PhD – Joint Pilot, co-sponsored with PMHARC||Neuropsychiatric complications of COVID19 in HIV: a clinical and 7T MRI Pilot Study|
|2022||Rebecca Stewart, PhD & Margaret Lowenstein, PhD – Joint Pilot, co-sponsored with PMHARC||Mobile Service Delivery in Response to the Opioid and HIV Epidemics in Philadelphia|
|2022||Cedric Bien-Gund, MD||Peer Mentors to Expand HIV Self-Testing and PrEP/ART for Medically Disconnected MSM|
|2022||Hansel Otero, MD||Brain Ultrasound in the Evaluation of Early Neurodevelopmental Differences between HIV-exposed Uninfected and HIV- unexposed Uninfected Newborns and Infants|
|2022||Aaron Richterman, MD, MPH||Mental Bandwidth in Pregnant Women with HIV|
|2022||Cagla Akay-Espinoza, MD||HIV viral dynamics and host-cell gene expression profiles in human induced pluripotent stem cell derived myeloid cells|
|2022||David Hill, MD, PhD||Influence of HIV/ART on Adipose Tissue Myeloid Suppressor Cells|
|2022||Sarita Sonalkar, MD||Development of an implementation strategy to integrate HIV pre-exposure prophylaxis into family planning care|
|2022||Elizabeth White, PhD||HPV Oncogene Diversity and lnflammation in HIV- and HIV+ Cancers|
|2022||Nancy Aitcheson, MD – Joint Pilot, co-sponsored with LDI||Implementation of Routine, Opt-out HIV Screening in Emergency Departments in West Philadelphia: Building on Success|
|2022||Stephen Bonett, PhD, RN – Joint Pilot, co-sponsored with LDI||Evaluating the implementation of low-threshold PrEP services in sexual wellness clinics|
|2022||Rebecca Stewart, PhD – Joint Pilot, co-sponsored with LDI||Feasibility and Acceptability of Harm Reduction Vending Machines in Philadelphia|
|2022||Daniel Teixeira da Silva, MD – Joint Pilot, co-sponsored with LDI||Enhancing HIV testing and PrEP Delivery in Substance Use Disorder Treatment Programs|
|2022||Jennifer McGuire, MD, MSCE – Joint Pilot, co-sponsored with PMHARC||Immune dysregulation and neurodegeneration in adolescent SIV infection: radiographic and neuropathologic correlates|
|2022||Yijing Su, PhD. – Joint Pilot, co-sponsored with PMHARC||Identification of molecular signature of HIV infected cells in CNS using single cell multi-omics technology|
|2021||Florence Momplaisir, MD, MSHP||Acceptability and feasibility of MAT and mobile application to support PrEP adherence in women with opioid use disorder|
|2021||Katharine Rendle, PhDh, MSW, MPH||Improving timeliness of cervical cancer care in women living with HIV in Botswana|
|2021||Ian Tietjen, PhD||Assessing “Mukungulu” as a novel, natural HIV latency reversal agent|
|2021||Jessie Torgersen, MD, MHS, MSCE||Evaluation of the validity of an automated electronic program to identify hepatic steatosis in HIV infected and uninfected patients within non-contrast abdominal CT scans|
|2020||Simon Lacey, PhD – Joint Pilot, co-sponsored with the Abramson Cancer Center||Development of Gamma-Delta T cells with CRISPR Knock-In of CAR19 into CCR5 Gene (gamma delta CAR19-CCR5KO) as a Therapy for HIV-Associated B cell Lymphomas|
|2020||Susan Coffin, M.D., MPH||Characterizing the Epidemiology and the Microbiology of Sepsis in HIV-exposed Neonates in Gaborone, Botswana|
|2020||Kyle Kampman, M.D.||Long-acting buprenorphine for high-risk opiate use disorder individuals|
|2020||Daniel Kulp, Ph.D.||DNA-launched nanoparticle vaccine design|
|2020||Florence Momplaisir, M.D., MSHP||Assessing attitudes, beliefs, and interest for pre-exposure prophylaxis (PrEP) in pregnancy and in the postpartum period|
|2020||Hamideh Parhiz, PharmD, Ph.D.||Targeted Delivery of engineered recombinase-encoding mRNA lipid nanoparticles for eradication of HIV|
|2020||Chamith Rajapakse, Ph.D.||Comprehensive MRI of the Hip in HCV and HIV/HCV Coinfected Patients|
|2019||Yehoda Martei, M.D. MSCE||Impact of Toxicity on Therapy Delivery and Outcomes in HIV-Infected Breast Cancer Patients|
|2019||Mohamed Abdel-Mohsen, PhD – Joint Pilot, co-sponsored with the Microbiome Program||Deciphering the Interactions Between Gut-associated Glycome and Microbiota During HIV Infection|
|2019||Merrian Brooks, DO, MS – Joint Pilot, co-sponsored with the Penn Mental Health AIDS Research Center||Expanding an Adapted Friendship Bench Near Peer Lay Counselor Intervention Pilot to Explore Mental Illness and Co-Occurring Substance Use/Abuse in Youth at Risk for and Living with HIV|
|2019||Aletha Akers, M.D.||Understanding HIV Testing Behavior Among Young, Urban, At-Risk Women Seeking Contraceptive Services|
|2019||Lily Brown, Ph.D.||PTSD, Substance Use, Sleep Disorders, and Suicide Risk in Persons Living With HIV|
|2019||Robert Carpick, Ph.D.||Characterization of Hydrogels as Lubricious Coatings for Intrarectal Products|
|2019||Sarita Sonalkar, M.D., M.P.H.||Integration of HIV Pre-Exposure Prophylaxis Screen into Care for Women with Abnormal and Undesired Pregnancies|
|2019||Jianxin You, Ph.D.||Discovering the Immune Evasion Mechanism of Merkel Cell Carcinoma, an HIV-associated Malignancy|
|2018||Mohamed Abdel-Mohsen, Ph.D.||Cell-surface Glycomic Signature Associated with Blood and Tissue HIV Reservoirs|
|2018||David Allman, Ph.D.||Sequential immunization and lasting humoral immunity|
|2018||Laurence Eisenlohr, VMD, Ph.D.||Processing of HIV-1 antigens for MHC class-II restricted presentation|
|2018||Shruthi Ravimohan, Ph.D.||Host genetic correlates of aberrant immune recovery and pulmonary dysfunction in HIV/TB patients initiating ART|
|2018||Oriol Sunyer, Ph.D.||Using an evolutionary old immune system for the discovery of broadly neutralizing HIV-1 epitopes|
|2018||Sarah Tishkoff, Ph.D.||Impact of maternal exposure to HIV and anti-retroviral therapy on DNA methylation state in HIV-uninfected newborns in Botswana: A pilot study|
|2017||C. Neill Epperson, MD – Joint Pilot, co-sponsored with ITMAT and the Chronobiology Program||Impact of Circadian Phase and Insomnia on Risk for Early Cognitive Decline Among HIV-Infected Males and Females|
|2017||Stewart Anderson, M.D.||A model system for the study of human macrophage synaptophagy of human forebrain synapses in HIV|
|2017||Surbhi Grover, M.D., M.P.H.||Treatment Outcomes in HIV Patients with Locally Advanced Breast Cancer Who Receive Pre-Operative Chemotherapy|
|2017||Michelle Johnson, Ph.D.||Robot Assisted Rehabilitation After HIV-Associated Stroke|
|2017||Laura Vella, M.D., Ph.D.||Circulating T Follicular Helper Subsets as a Periscope into the Lymph Node and a Biomarker of HIV Resevoir|
|2017||Sarah Wood, M.D.||Social Support as Facilitator of Adherence to HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men|
|2016||Carsten Skarke, PhD – Joint Pilot, co-sponsored with ITMAT and the Chronobiology Program||Mapping the Human HIV Chronobiome|
|2016||Emile Mohler, M.D.||Evaluation of cardiovascular risk in patients infected with HIV|
|2016||Courtney Schreiber, M.D., M.P.H.||Contraceptive service delivery with a cervical cancer prevention program in Botswana: a hybrid type 2 clinical intervention and implementation strategy|
|2016||Anastasios Vourekas, Ph.D.||The role of RNA helicase DDX3X in the activation of HIV replication in latently infected T cells|
|2016||AT Charlie Johnson, Ph.D.||Graphene-Aptamer Biosensor to Detect Tenofovir in Urine|
|2016||Chelsea Morroni, Ph.D., M.P.H.||SACHOICE Study: Southern African Contraception and HIV Study: Options for Implant Continuation on Efavirenz|
|2016||Changchun Liu, Ph.D., M.S.||A Novel Point-of-Care Isothermal PCR Assay for Meningitis Diagnosis in Low Resource Settings|
|2015||Nadia Dowshen, M.D. (Pediatrics)||Development of a novel Mhealth intervention to improve adherence to antiretrovial therapy among HIV+ youth|
|2015||Joseph Jarvis, M.D. (Medicine/ID); Madisa Mine, Ph.D. (Ministry of Health, Botswana Government)||The feasibility and potential utility of cryptococcal antigen screening to reduce early mortality in patients initiating Antiretrovial Therapy in BOTS: a pilot study|
|2015||Michael Mullen, M.D., MSCE (Neurology); David Bearden, M.D., (Neurology at CHOP)||HIV and stroke in Botswana|
|2015||Laura Su, M.D., Ph.D., (Medicine/Rheumatology)||Characterizing influenza-specific follicular helper CD4+ T cells in the lymph nodes of HIV patients on anti-retrovial therapy|
|2015||Anne Teitelman, PhD, FNP-BC, FAANP, FAAN (School of Nursing); Yukiko Washio, Ph.D. (TRI)||What is the impact of substance use and violence on HIV testing among postpartum women?|
|2015||Ramin Herati, Ph.D. (Microbiology; E. John Wherry, Ph.D. (Microbiology)||Assessment of serological and cellular inflammation to predict influenza vaccine responses in HIV-infected individuals|
|2014||Malitta Engstrom, Ph.D., LCSW (School of Social Policy & Practice)||Community reinforcement and family therapy with men leaving prison and their female partners|
|2014||David Issadore, Ph.D (Bioengineering), Gregory Bisson, M.D. (Medicine)||The ultra-sensitive detection of rare mycobacterium tuberculosis using a µHall chip|
|2014||Helen Koenig, M.D., MPH. (Medicine, ID), Karam Mounzer, M.D. (Medicine)||Validation of a urine assay for the measurement of tenofovir levels as a means of monitoring adherence to truvada given as pre-exposure prophylaxis for HIV prevention|
|2014||Emilio Parrado, Ph.D. (Sociology), Felicia Lewis, M.D., CDR, USPHS (Philadelphia Dept of Health)||HIV risks and health care access among Mexican and Central American immigrants in Philadelphia|
|2014||Xiaolu Yang, Ph.D. (Cancer Biology), Jim Riley, Ph.D. (Microbiology)||Restriction of HIV by TRIM5a: mechanism and potential therapeutic application|
|Abass Alavi, M.D. (Radiology), Pablo Tebas, M.D. (Medicine/ID)||Assessment of cardiovascular and central nervous system complications of HIV/AIDS by PET/CT imaging|
|2013||Katharine Bar, M.D. (Medicine/ID)||Viral Dynamics of HIV-1 Rebound Viremia|
|2013||Henry Kranzler, M.D. (Psychiatry), David Metzger, Ph.D. (Psychiatry)||Cognition as a Potential Mediator of Alcohol Use and Poor ART Adherence in HIV+ Drinkers|
|2013||Lilie Lin, M.D. (Radiation Oncology), Surbhi Grover (Medicine), Doreen-Ramogola-Masire (Botswana-UPenn)||Impact of HIV infection and treatment on tolerability of cervical cancer therapy|
|2013||Deirdre Sawinski, M.D. (Medicine/ Renal), and Emily Blumberg M.D. (Medicine)||Effect of rATG on HIV reservoirs in HIV+ kidney transplant recipients|
|2013||Jean Scholz, Ph.D. (Pathology & Lab Med), Michael Cancro (Pathology & Lab Med)||Are potentially broadly neutralizing clonotypes eliminated at peripheral selection checkpoints?|
|2012||David Artis, Ph.D. (Microbiology), Gregory Sonnenberg, Ph.D. (Microbiology)||Immune regulation of intestinal barrier function following SIV infection|
|2012||Paul Bates, Ph.D. (Microbiology)||NFkB activation by Tetherin|
|2012||Haim H. Bau, Ph.D. (Engineering), Changchun Liu, Ph.D. (Engineering), and Robert Gross, M.D., M.S.C.E. (Medicine/ID; CCEB)||Point of Care, Integrated System for Molecular Detection of HIV|
|2012||Hans-Peter Kohler, Ph.D. (Sociology) and Iliana Kohler, Ph.D. (PSC)||Mental Health, HIV and Aging in a poor high-risk disease environment: A pilot study in rural Malawi|
|2011||Jennifer Cohn, M.D. (Medicine/ID)||Mobile telecommunication solutions to improve HIV patient care at the community level in Kenya|
|2011||Ron Collman, M.D. (Med/Pulmonary) and Anjana Yadav, Ph.D. (Medicine); Dennis Kolson, M.D., Ph.D. (Neurology)||Stain modulation of monocyte activation: a pilot study for potential use in NeuroAIDS|
|2011||Dennis Dlugos, M.D., M.S.C.E (Neurology at CHOP) and David Bearden, M.D. (Neurology at CHOP)||Risk Factors for Seizures in Children with HIV/AIDS in Botswana|
|2011||David Metzger, Ph.D. (Psychiatry) and Sumedha Chhatre, Ph.D. (Psychiatry)||Effects of stress reduction on chronic immune activation and inflammation|
|2011||Shikata Mudakha, M.D. (Medicine/ID) and Mary Kestler, M.D. (Medicine/ID); Harvey Friedman, M.D. (Medicine/ID)||Developing a TB screening algorithm for coughers presenting for inpatient care in an arear of high HIV prevalence|
|2011||Virginia Stallings, M.D. (Pediatrics, CHOP)||Botswana Vitamin D Supplementation Study in HIV/AIDS|
|2010||Sita Awasthi, Ph.D. (Medicine/ID)||To establish a humanized mouse model for HSV-2 and HIV-1 Co-infection|
|2010||Ron Collman, M.D., (Med/Pulmonary) and Nicola Zetola, M.D. (Botswana)||Alcoholism and MDR TB in HIV patients in Botswana|
|2010||Andrea Doyle, Ph.D. (Social Policy & Practice) and Jeffrey Draine, Ph.D., (Social Policy & Practice)||Healthcare engagement of women who test positive for HIV in a vaccine trial|
|2010||Robert Gross, M.D., MSCE (Medicine) and Elizabeth Lowenthal, M.D.||Psychosocial Assessments of HIV-infected children and adolescents in Botswana|
|2010||Carrie Kovarik, M.D. (Dermatology) and Rahat Azfar, M.D.||The use of mobile telemedicine for remote diagnosis of HIV-infected patients in Botswana|
|2010||Daniel Langleben, M.D. (Psychiatry) and Daniel Romer, Ph.D. (Annenberg)||Functional MRI of Brain Response to HIV Prevention Public Service Announcements|
|2010||Vincent Lo Re, M.D., (Medicine, ID) and Mary Leonard, M.D., MSCE||A structural approach to bone disease due to Hepatitis C co-infection in HIV|
|2010||Zhengyu Ma (CHOP) and Dennis Discher, Ph.D. (Engineering)||Probing the mechanism of HIV TCR specificity using atomic force microscopy|
|2010||Jon Merz, J.D., Ph.D. (Medical Ethics) and Francis Barchi, M.S.||Botswana Ethics Training Initiative: Using web-based tools to enhance learning and skills-development in research ethics training of host-country HIV/AIDS|
|2010||Andrew Steenhoff, M.D. (Pediatrics) and Nicola Zetola, M.D.||Novel diagnostics for pediatric tuberculosis|
|2009||Stefania Gallucci, M.D.(Pediatrics), and David Weiner, Ph.D. (Path/Lab Medicine)||Clonogenic Progenitors of Dendritic Cells as Novel Antigen Carrier in anti-HIV|
|2009||Toorjo Ghose, M.S.W., Ph.D. (Social Policy & Practice)||Implementing PATH-India: Reducing HIV Risk Among the Dually Diagnosed in India|
|2009||John Kempen, M.D, M.H.S., M.P.H., Ph.D. (Opthalmology), and Maureen Maguire, Ph.D. (Opthalmology)||Pilot Study in Preparation for the Intravitreous Ganciclovir-Valganciclovir Cytomegalovirus Retinitis Trial (GIVCyT)|
|2009||Steven Marcus, Ph.D. (Social Policy & Practice), and Julie Cederbaum, M.S.W.,M.P.H. (Social Policy & Practice)||HIV Serostatus and its Influence on Mother Influence Behaviors and Adolescent Engagement in HIV Risk Behaviors|
|2009||Doreen Ramogola, M.D. (Women’s Health, University of Botswana), and Harvey Friedman, M.D. (Medicine, ID)||Epidemiology of HPV Infection in HIV-infected Women with Precancerous Cervical Lesions in Botswana|
|2009||Samir Shah, M.D., M.S.C.E.. (Pediatrics, Epidemiology), and Zsofia Szep, M.D. (Medicine, ID)||Association of Serum Vitamin D Levels and Insulin Resistance Among Patients Infected w/Human Immunodeficiency Virus|
|2008||Frederic Bushman, Ph.D. (Microbiology)||The Macaque Gut Microbiota and SIV Infection|
|2008||Branch Coslett, M.D. (Neurology) and Kathy Lawler, M.D. (Neurology)||Assessment of HIV-Related Dementia and Depression in Botswana|
|2008||Roy Kim, M.D. (Pediatrics) and Ian Frank, M.D. (Medicine, ID)||Effects of Recombinant IGF-I in HIV-Associated Metabolic Disease|
|2008||Susan Ross, Ph.D. (Microbiology)||Development of an in vivo Model to Study APOBEC3G/vif Interaction|
|2008||Courtney Schreiber, M.D. (OB/GYN)||How to Avoid Pregnancies in HIV Prevention Trials: a Case-Control Study and Point-of-Care Questionnaire|
|2008||Anne Teitelman, Ph.D. (Nursing); Loretta Sweet Jemmott, Ph.D. (Nursing); Therese S. Richmond, Ph.D. (Nursing); and William Holmes, M.D. (Medicine/Epidemiology)||HIV/STI Risk Reduction for African-American Adolescent Girls: Addressing the Context of Partner Abuse|
|2007||John B. Jemmott, III, Ph.D. (Psychiatry) and G. Anita Heeren, M.D., MSc., Ph.D. (Annenberg School of Communication)||HIV/STI Risk Reduction for African American Men|
|2007||Shane T. Jensen (Statistics, Wharton) and Jon D. McAuliffe (Statistics, Wharton)||Spatially Varying Evolutionary Models of Viral Escape Response|
|2007||Dennis Kolson, M.D., Ph.D. (Neurology) and Julio Martin-Garcia, Ph.D. (Microbiology/Immunology, Drexel)||Neurotropism and Neurovirulence of Subtype C HIV-1 Isolates from Botswana|
|2007||Ian C. MacMillan, MBA, DBA (Wharton); Darren Linkin, M.D. (Medicine, ID); James Thompson, MBA, Ph.D. (Wharton); Alan Abrahams, Ph.D. (Wharton); Diana Dickenson, M.D. (Clinician in Gaborone, Botswana); and Peter Ehrenkranz, M.D., MPH (Clinical Scholars, Penn)||A Pilot Study of Cellular Phone Text Message Reminders to Improve HIV Medication Adherence in the Developing World|
|2007||Erle Robertson, Ph.D. (Microbiology) and Gregory Bisson, M.D., M.S.C.E. (Medicine, ID)||Identification of an Etiological Basis Associated with Ocular Surface Squamous Neoplasia|
|2007||Guido Silvestri, M.D. (Pathology and Laboratory Medicine) and Ian Frank, M.D. (Medicine, ID)||Mucosal Immune Activation in HIV-infected Patients|
|2006||Yair Argon, Ph.D. (Pathology and Laboratory Medicine) and Stefania Gallucci, M.D. (Pediatrics, Children’s Hospital)||Augmenting the Presentation of HIV Peptides to T cells using an Engineered Chaperone Protein|
|2006||Michael Betts, Ph.D. (Microbiology) and Ian Frank, M.D. (Medicine, ID)||Modulation of HIV-specific CD8+ T cell Function and Control of HIV Replication During and After Cessation of HAART|
|2006||Arthur Caplan, Ph.D. (Medicine, Medical Ethics)||An Ethical Framework for HIV Vaccine Research|
|2006||Sridhar Hannenhalli, Ph.D. (Genetics) and Frederic Bushman, Ph.D. (Microbiology)||Computational Analysis of HIV-1 Integration in the Human Genome|
|2006||Nancy Hanrahan, Ph.D. (School of Nursing)||Quantifying Nurse Interventions in the Treatment of Individuals with Serious Mental Illness and HIV|
|2005||Randy Cron (Pediatrics, Children’s Hospital) and Pablo Tebas (Penn Medicine, ID)||NFAT Activity in CsA-Treated HIV-1-Infected Individuals|
|2005||Stefania Gallucci (Pediatrics, Children’s Hospital) and Terri Finkel (Pediatrics, Children’s Hospital)||Activating Anti-HIV Dendritic Cells by Abnormal Cell Death|
|2005||Edward George (Statistics, Wharton)||Exploratory Markov Modeling of Discrete Biomarkers|
|2005||David Oslin (Medicine, Psychiatry)||Aging Among HIV-infected Individuals as a Risk for Cognitive Decline and Poor Adherence|
|2005||Pablo Tebas (Medicine, ID)||Prevalence of HCV and HBV Among HIV Positive Patients in the Dominican Republic|
|2004||Harvey Friedman (Medicine, ID) and Gregory Bisson (Medicine, ID)||Virologic Effectiveness, Predictors of Virologic Failure and Development of a Clinical Prediction Rule for Virologic Success in the Botswana National ARV Program|
|2004||John Detre (Neurology) and Beau Ances (Neurology)||Brain Activation Using fMRI in Asymptomatic, Mild Cognitive Motor Deficit, and AIDS Dementia Patients|
|2004||Muredach P. Reilly (Medicine, Cardiovascular Division)||Pilot Study of the Genetics of ART-associated Dyslipidemia in HIV|
|2004||Hao Shen (Microbiology)||Role of CD4 Help in Heterologous Prime-Boost Immunization|
|2003||Li-Wei Chao (Anesthesiology, Children’s Hospital) and Mark Pauly (Wharton)||Educator and Pupil Training in HIV/AIDS in South Africa|
|2003||Andrew Dancis (Medicine, Hematology/Oncology)||Roles for Three Distinct Iron Uptake Systems in Mucosal Infections by Candida albians|
|2003||Paul Lieberman (The Wistar Institute)||Regulation of Kaposi’s Sarcoma-Associated Virus Reactivation|
|2003||Gerd Maul (The Wistar Institute)||Improvement for Gag DNA Vaccine Vector by Nuclear Targeting|
|2003||Barbara Turner (Medicine) and Kathleen Brady (Medicine)||Unlinked Seroprevalence Testing of Hepatitis C in Inpatients|
|2002||Jean Boyer (Pathology and Laboratory Medicine)||A Polarized Th2 Immune Response Can Decrease HIV-1 Vaccine Efficacy|
|2002||Robert Doms (Microbiology)||Analysis of Envs from HIV-infected Children in Nairobi, Kenya|
|2002||J. Kevin Foskett (Physiology)||Interaction of HIV Nef with the Inositol Trisphophate Receptor Intracellular Ca2 Release Channel|
|2002||Kaivan Munshi (Economics, School of Arts and Sciences)||Marriage and Sexual Behavior: With an Application to Urban Migrants in Kisumu, Kenya|
|2002||James Riley (Pathology and Laboratory Medicine)||Control of CCR5 Expression in Primary CD4 T Cells|
|2001||Michael Blank (Psychiatry) and Aileen Rothbard (Psychiatry)||Co-Occurrence of HIV/AIDS Among Persons with Severe Mental Illness|
|2001||Bruce Freedman (Animal Biology, School of Veterinary Medicine)||Mechanism of HIV-1 gp120 Induced Capping on Primary Human Macrophages|
|2001||Samuel Parry (Ctr for Research on Reproduction and Women’s Health)||Transmission of Human Immunodeficiency Virus Across the Placenta|
|2001||William Swiggard (Medicine, ID)||Interactions of Circulating Human Dendritic Cells with HIV-1|
|2000||Jeffrey Field (Pharmacology)||Role of Pak kinases in Kaposi’s Sarcoma|
|2000||Stuart Isaacs (Medicine, ID)||Development of Novel Recombinant Vaccinia Virus Based anti-HIV Vaccines|
|2000||Robert Ricciardi (Microbiology, School of Dental Medicine)||A Novel Approach for Identifying HHV-8 Anti-virals|
|2000||Antonia Villarruel (School of Nursing)||Effectiveness of an HIV Risk Reduction Intervention for Spanish-speaking Latino Youth|
|2000||Susan Watkins (Sociology) and Jere Behrman (Economics)||Social Science Aspects of Intergenerational and Intragenerational Interactions Related to HIV/AIDS in a High HIV/AIDS Incidence sub-Saharan Population|